LogicBio Therapeutics racks up $45 mln Series B

LogicBio Therapeutics Inc, which is focused on gene therapies for orphan pediatric diseases, has raised $45 million in Series B funding. Arix Bioscience led the round with participation from other investors that included OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, SBI and OrbiMed Israel Partners. In addition to the funding, Dr. Daniel O’Connell of Arix Bioscience has been appointed to LogicBio’s board of directors.

Source: Press Release